



Press release

Successful placement of Inaugural €300-Million Issue of 7-Year Bonds

Marcy l'Etoile, France, October 7, 2013 - bioMérieux, a world leader in the field of *in vitro* diagnostics, announced the placement to institutional investors of its first issue of seven-year euro-bonds for a total amount of €300 million. The bonds mature on October 14, 2020 and pay interest at an annual rate of 2.875%. The issue has been more than four times over-subscribed.

Mid-October 2013, the bonds will be admitted to trading on the regulated market of NYSE Euronext Paris.

Jean-Luc Belingard, bioMérieux's Chairman and Chief Executive Officer, said: « We are pleased with the success of this inaugural bond issue, endorsing investor confidence in bioMérieux's strategy of specialization and innovation, the Company's strong international ambition and its financial strength. Proceeds from the bond issue will help to finance bioMérieux's development respecting the vision that has guided us for 50 years".

That bond issue will enable bioMérieux:

- To lengthen the average maturity of its debt under favorable financial conditions;
- To diversify its sources of financing, in addition to its existing syndicated lines of credit;
- To contribute to funding the acquisition of the U.S. company BioFire, whose completion is expected to close by the end of the fiscal year or in early 2014.

BNP Paribas, HSBC and Natixis are lead managers for the bond issue. CA CIB and Société Générale are passive book runners.

The bonds have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The bonds are being offered outside the United States in reliance on Regulation S under the Securities Act ("Regulation S") and may not be offered, sold or delivered within the United States or to, or for the account of, U.S. persons (as defined in Regulation S).

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2012, revenues reached €1,570 million with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com.

CONTACTS

Investor Relations

bioMérieux

Isabelle Tongio

Tel: : + 33 4 78 87 22 37

investor.relations@biomerieux.com
m

Media Relations

bioMérieux

Aurore Sergeant

Tel: : + 33 4 78 87 51 97

media@biomerieux.com

Image Sept

Laurence Heilbronn

Tel: : + 33 1 53 70 74 64

lheilbronn@image7.fr

Claire Doligez

Tel: : + 33 1 53 70 74 48

cdoligez@image7.fr